Medeon Biodesign, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 02, 2022
Share
Medeon Biodesign, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 41.52 million compared to TWD 9.75 million a year ago. Net loss was TWD 124.64 million compared to TWD 178.81 million a year ago. Basic loss per share from continuing operations was TWD 1.3524 compared to TWD 1.9524 a year ago. Diluted loss per share from continuing operations was TWD 1.3524 compared to TWD 1.9524 a year ago. Basic loss per share was TWD 1.3524 compared to TWD 1.9524 a year ago. Diluted loss per share was TWD 1.3524 compared to TWD 1.9524 a year ago.
For the nine months, sales was TWD 261.41 million compared to TWD 59.01 million a year ago. Net loss was TWD 249.21 million compared to net income of TWD 2,185.08 million a year ago. Basic loss per share from continuing operations was TWD 2.7048. Diluted loss per share from continuing operations was TWD 2.7048. Basic loss per share was TWD 2.7048 compared to basic earnings per share of TWD 23.8287 a year ago. Diluted loss per share was TWD 2.7048 compared to diluted earnings per share of TWD 23.8287 a year ago.
Medeon Biodesign, Inc. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of medical equipment. The Company's main products include medical apparatus and instruments used in laparoscopic minimally invasive surgeries and cardiac catheter-related minimally invasive surgeries. The Company distributes its products in domestic market and to overseas markets.
MEDEON BIODESIGN, INC. 
